Doxylamine/pyridoxine transdermal patch - Aequus Pharmaceuticals

Drug Profile

Doxylamine/pyridoxine transdermal patch - Aequus Pharmaceuticals

Alternative Names: AQS-1303; Doxylamine succinate/pyridoxine hydrochloride - Aequus Pharmaceuticals; Pyridoxine/doxylamine transdermal patch

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aequus Pharmaceuticals
  • Class Antiemetics; Picolines; Pyridines; Sedating antihistamines; Small molecules; Vitamins
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Nausea and vomiting

Highest Development Phases

  • Clinical Phase Unknown Nausea and vomiting

Most Recent Events

  • 19 Jul 2018 AQS 1303 - Aequus Pharmaceuticals is available for licensing in Europe as of 19 Jul 2018.
  • 22 Jun 2018 Aequus Pharmaceuticals and Corium International expands their agreement to advance clinical development of AQS 1303 for the treatment of Nausea and Vomiting
  • 07 Sep 2017 Pharmacokinetics and adverse events data from a proof-of-concept trial in Nausea and vomiting released by Aequus Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top